The healthcare industry is poised for growth driven by aging populations, technological advancements, and increased ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Today's Research Daily features the Q4 earnings season scorecard and updated analyst reports on 16 major stocks, including Meta Platforms (META), Mastercard (MA) and Adobe (ADBE), as well as two micro ...

The midstream energy giant reported solid fourth-quarter results, with notable advances in revenue and operational metrics.

Learn more about whether Marathon Petroleum Corporation or Pembina Pipeline Corporation is a better investment based on ...

In the fast-paced world of investing, staying ahead requires good ideas and timely decisions. This article highlights five ...

EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): ADMA Biologics's EV/EBITDA ratio of 39.64 exceeds industry averages, indicating a premium ...

Results Very strong Q4 at +6.3% Ending 2024 as the world's largest advertising group February 4, 2025 Ending 2024 as world's largest advertising group: +6.3% organic growth ...

Results Very strong Q4 at +6.3% Ending 2024 as the world's largest advertising group February 4, 2025 Ending 2024 as world's largest advertising group: +6.3% organic growth ...

The TSX parent reported adjusted earnings per share of 48 cents, topping the Street’s expectation by 4 cents as organic ...

technology revenues recorded a strong increase by +33.8% compared to 2023, to €80m, and +47.1% Q4/Q4; Amundi Technology ...

Pro Medicus is in a strong financial position. As of June 2024, it had AUD 155 million in net cash, and we forecast the company to continue holding net cash over our explicit 10-year forecast period.